

REMARKS

Consideration of the application and the amendments above is respectfully requested. Claims 1-27, 29-32 and 37-40 are pending. Claims 28, 33-36 and 41-46 of the present application have been canceled.

In the specification, the new paragraph to be inserted on page 1, line 5, was added after the "TITLE OF THE INVENTION" paragraph on page 1, lines 1-3 and before the "FIELD OF INVENTION" paragraph on page 1, lines 5-11, to provide the priority of the present application. No new matter is being added to the above-captioned application by the submission of the Abstract of the Invention, because it is identical to that in the priority document PCT/US03/27892. For the Examiner's convenience, a separate sheet for the Abstract of the Invention (page 153) is enclosed for inclusion with the specification of the U.S. National Phase Application being filed.

Claims 27, 30, 31, and 40 are currently amended. Claim 27 has been amended to add "diabetes mellitus"; support for this addition can be found in original Claim 28. Claims 30 and 31 have been amended to add "a melanin-concentrating hormone receptor antagonist, a bombesin receptor subtype 3 agonist, a ghrelin receptor antagonist or a dipeptidyl peptidase IV inhibitor" as second active ingredients; support for these additions can be found in original Claims 42 and 43. Claim 40 has been amended to add "or prevention"; support for this addition can be found in original Claim 41. No new matter has been added to the currently amended claims by these additions since support for these additions is found in the original claims. Claims 28, 33-36 and 41-46 of the present application have been canceled.

Applicants respectfully contend that the application is allowable, and a favorable response from the Examiner is earnestly solicited.

Respectfully submitted,

By

  
Baerbel R. Brown, Reg. No. 47,449  
Attorney for Applicants

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
Tel: (732)594-0672

Date: February 28, 2005